The paper presents the results of clinical use ofglargin insulin (Lantus) in the work of the Moscow endocrinological service. It gives an assessment of the effectiveness, safety, and satisfaction with treatment for diabetes mellitus (DM). The data on a follow-up of patients receiving Lantus as basal insulin in real clinical practice are shown. The use ofglargin insulin (Lantus) as basal insulin not only in the short (3-month) course of therapy, but also in the long (1-year) course is demonstrated to considerably improve gfycemic control in patients with types 1 and 2 DM. The improvement of carbohydrate metabolic parameters is not attended by the increase in the dose of basal insulin in patients with type 1 DM while the increase in the dose of Lantus was observed in patients with type 2 DM as compared with that ofNPH insulin. The greatest improvement in the parameters ofglycemia was seen 1 year following the use of Lantus in a maintaining dose. Almost all patients with types 1 and 2 expressed their satisfaction with treatment and their wish to continue Lantus therapy. The results obtained from this study promoted the integration of the accumulated clinical experience into the work of the whole endocrinological service of Moscow.
